Innovate UK welcomes global firm to Cell & Gene Catapult centre
TCR2 Therapeutics will become the first international organisation to work with the Cell and Gene Therapy Catapult manufacturing centre.
Innovate UK, part of UK Research and Innovation, yesterday welcomed the announcement that immunotherapy company, TCR2 Therapeutics, is to become the first US organisation to work with the Cell and Gene Therapy (CGT) Catapult at its Stevenage manufacturing centre. TCR2 has selected the facility to establish a site for global manufacturing and capability development to advance novel T cell receptor therapies for patients suffering from cancer.
Dr Ian Campbell, Interim Executive Chair, Innovate UK yesterday said:
By choosing to work with the Cell & Gene Therapy Catapult manufacturing centre, TCR2 Therapeutics demonstrates to the world that the UK is a global leader in this sector. Advanced cell and gene therapies show great promise in treating conditions such as cancer. It is vital to support research and development that could result in huge improvements in patient outcomes.
Boosted by investment through the government’s modern Industrial Strategy and the life sciences sector deal, the UK can realise both the commercial and societal benefits from these advances in this vital and thriving sector.
Dr Kath Mackay, Interim Director – Ageing Society, Health & Nutrition, Innovate UK, added:
The decision by TCR2 Therapeutics to establish a presence at the Cell & Gene Therapy Catapult manufacturing centre is a major international vote of confidence in the UK life sciences sector. The Cell and Gene Therapy Catapult manufacturing centre is a world-leading facility, bringing the manufacture of pioneering treatments closer to patients. The decision recognises the level and maturity of government investment into UK manufacturing capability and the associated supply chain.
UK Research and Innovation, through the government’s Industrial Strategy Challenge Fund, backs this crucial component of the modern Industrial Strategy, building the jobs and industries of tomorrow. We have underlined our support by also funding three new Advanced Therapy Treatment Centres to complement the work of the manufacturing centre. Working across the UK, this network will support the roll-out of cell and gene therapies, bringing together expert clinicians, researchers, scientists, developers and private companies to demonstrate the benefits for patients.
The CGT Catapult manufacturing centre in Stevenage, opened in April 2018, is backed by more than £60 million of government investment, including funding from Innovate UK and the Industrial Strategy Challenge Fund (ISCF). TCR2 joins advanced therapy companies Adaptimmune, Autolus, Cell Medica, and Freeline.
Working with the manufacturing centre are the three UK Advanced Therapies Treatment Centres, which were awarded £21 million in through the ISCF Medicines Manufacturing challenge. The centres are collaborative ventures between industry, academic and NHS partners. They comprise the Innovate Manchester Advanced Therapy Centre Hub (iMATCH), the Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC, comprising Birmingham, Wales and Nottingham) and the Northern Alliance Advanced Therapies Treatment Centre (NAATTC, comprising Scotland, Newcastle and Leeds).
Latest News from
Modernising access to smart energy data: apply for contracts18/10/2019 09:10:00
Organisations can apply for a share of up to £1.9 million to design and build systems that will modernise the use of data in the energy sector.
Developing future GNSS: SBRI opportunity16/10/2019 12:25:00
UK organisations can express an interest in seeking funding to develop receivers for a future UK global navigation satellite system (GNSS).
Work with China to transform food production: apply for funding15/10/2019 09:10:00
Businesses can apply for a share of up to £5 million to work with Chinese partners on developing new smart farming technologies.
New Innovate UK brand launched as part of unified UKRI identity11/10/2019 09:10:00
A new brand for Innovate UK was launched yesterday as part of a unified identity for UK Research and Innovation (UKRI).
Revolutionising cancer treatment with genomics: apply for funding07/10/2019 12:15:00
Businesses can apply for a share of up to £5.4 million for projects that apply whole genome sequencing to the analysis of cancer.
Smart funding: open to innovative businesses from any sector03/10/2019 09:10:00
Businesses can apply for a share of £25 million in Smart funding to support innovative ideas with commercial potential in any area of the economy.
World-leading advances in aerospace: apply for funding02/10/2019 12:20:00
Organisations can put forward ideas for new design and propulsion technologies that could drive growth in the UK aerospace industry.
Groundbreaking technologies for aerospace: apply for funding02/10/2019 09:10:00
SMEs can apply for a share of £2.5 million to develop innovative technologies that could win new business in the aerospace sector.